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S U M M A R Y
Objective: This study aimed to systematically evaluate maggot debridement therapy (MDT) in the
treatment of chronically infected wounds and ulcers.
Methods: We performed a meta-analysis referring to the PRISMA statement (Preferred Reporting Items
for Systematic Reviews and Meta-Analyses). We searched for published articles in the following
databases: PubMed, Web of Science, Embase, Wanfang (Chinese), and the China National Knowledge
Infrastructure (CNKI). The latest search was updated on March 14, 2014. For dichotomous outcomes, the
effects of MDT were expressed as the relative risk (RR) and 95% conﬁdence interval (CI). For continuous
outcomes with different measurement scales, we calculated the standardized mean difference (SMD).
The pooled effects were estimated using a ﬁxed effect model or random effect model based on the
heterogeneity test. Subgroup analyses were performed according to the types of wounds or ulcers.
Results: MDT had a signiﬁcantly increased positive effect on wound healing compared with conventional
therapies, with a pooled RR of 1.80 (95% CI 1.24–2.60). The subgroup analysis revealed that the combined
RRs were 1.79 (95% CI 0.95–3.38) for patients with diabetic foot ulcers (DFU) and 1.70 (95% CI 1.28–2.27)
for patients with other types of ulcers. The time to healing of the ulcers was signiﬁcantly shorter among
patients treated with MDT, with a pooled SMD of 0.95 (95% CI 1.24, 0.65). For patients with DFU, the
SMD was 0.79 (95% CI 1.18, 0.41), and for patients with other types of ulcers, the SMD was 1.16
(95% CI 1.63, 0.69).
Conclusion: MDT not only shortened the healing time but also improved the healing rate of chronic
ulcers. Therefore, MDT may be a feasible alternative in the treatment of chronic ulcers.
 2014 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-SA license (http://creativecommons.org/licenses/by-
nc-sa/3.0/).
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Chronic wounds, such as pressure sores and diabetic or vascular
ulcers, are associated with high morbidity and, to a lesser extent,
mortality.1 Chronic wounds are notoriously difﬁcult to treat
because they usually take the form of non-healing ulcers with
ﬁbrotic tissue, dead necrotic slough, and multiple infections.2 An
important issue in wound management is the process called
debridement,3 which is deﬁned as the removal of foreign debris
and devitalized or contaminated tissues from a wound bed so that* Corresponding authors.
E-mail addresses: wap454hospital@163.com (A. Wang), jmwang@njmu.edu.cn
(J. Wang).
http://dx.doi.org/10.1016/j.ijid.2014.03.1397
1201-9712/ 2014 The Authors. Published by Elsevier Ltd on behalf of International So
license (http://creativecommons.org/licenses/by-nc-sa/3.0/).the surrounding healthy tissues are exposed.4 Clinicians may
debride wounds using various methods, including surgery,
conservative sharp, high-pressure ﬂuid irrigation, ultrasonic mist,
autolysis, or enzymatic agents.4
One of the ‘old’ techniques in wound care is maggot
debridement therapy (MDT). MDT is also known as maggot
therapy, biodebridement, or larval therapy. In MDT, live and
‘medical-grade’ ﬂy larvae are applied to the patient’s wounds to
achieve debridement, disinfection, and, ultimately, wound heal-
ing.5 MDT is indicated for open wounds and ulcers that contain
gangrenous or necrotic tissues with or without infection.6
MDT uses freshly emerged and sterile larvae of the common
green-bottle ﬂy, Phaenicia (Lucilia) sericata, which is a type of
artiﬁcially induced myiasis raised under controlled clinicalciety for Infectious Diseases. This is an open access article under the CC BY-NC-SA
Figure 1. Flow diagram of the study selection procedure.
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effects on wounds and ulcers, including debridement, disinfection,
and enhanced healing.7 The beneﬁcial effects of using larvae were
ﬁrst noted in 1557,8 but with the introduction and widespread use
of antibiotics in the 1940s, it was gradually neglected by doctors.9
In recent years, with the rising incidence of drug resistance, there
has been renewed interest in using maggots in chronic wound
management,9 particularly in treating wounds infected with
methicillin-resistant Staphylococcus aureus (MRSA) and other
drug-resistant pathogens.1
Current evidence supporting MDT for chronically infected
lesions comes from several small clinical trials. To systematically
summarize the overall effects of MDT in treating chronic wounds,
we performed a meta-analysis by combining the results from
different studies with the hope of providing scientiﬁc evidence for
future clinical applications.
2. Methods
2.1. Data collection
This meta-analysis was conducted in accordance with the
guidelines of the Preferred Reporting Items for Systematic Reviews
and Meta-Analyses statement (PRISMA).10 We searched for
published articles in electronic databases including PubMed,
Web of Science, Embase, Wanfang (Chinese), and the China
National Knowledge Infrastructure (CNKI) using the following
terms and their combinations: [‘maggot therapy’ OR ‘maggot
debridement therapy’ OR ‘larval therapy’ OR ‘larval debridement
therapy’ OR ‘biodebridement’ OR ‘biosurgery’] AND [‘wound’ OR
‘ulcer’]. The latest search was updated on March 14, 2014.
Additional studies were identiﬁed from the references listed in
the articles retrieved.
2.2. Selection criteria
Studies were included in this meta-analysis if they met the
following criteria: (1) provided at least one of the following
outcomes: healing rate, time to healing, incidence of infection,
amputation rate, antibiotic-free days, or antibiotic usage; (2)
compared maggot or larval therapy with other therapies (i.e.,
conventional therapy); (3) treated chronic wounds or chronically
infected lesions; and (4) a relative risk (RR) with a 95% conﬁdence
interval (CI) or a mean with a standard deviation was reported or
could be calculated from the data presented in the article. The
exclusion criteria were (1) duplicated publications, and (2) studies
published in any language other than English or Chinese.
2.3. Data extraction
Two graduate students independently read articles and
extracted data using a standardized form. Extracted information
included the name of the ﬁrst author, year of publication, country,
ulcer or wound type, study design, intervention and control
methods, age, number of study subjects, and clinical outcomes. If
published data were not available for validity assessments or
outcome estimations, we contacted the authors to obtain more
information. Discrepancies were resolved by discussion among the
research group members.
2.4. Quality assessment
We evaluated the included studies using the quality checklist
recommended by the Cochrane handbook for randomized
controlled trials (RCTs).11 The risk of bias among clinical trials
was assessed based on the following domains: random sequencegeneration, allocation concealment, blinding of participants and
personnel, blinding of outcome assessment, incomplete outcome
data, selective reporting, and other sources of bias. In addition, the
Newcastle–Ottawa Scale (NOS) was used to evaluate the non-
RCTs.12 The maximum score was 4 for the selection of study
groups, 2 for the comparability of groups, and 3 for the
ascertainment of outcomes or exposures. The maximum NOS
score was 9, and studies with a score 6 were considered to be of
relatively high quality.
2.5. Statistical analysis
We carried out statistical analyses using Stata 11.0 software
(StataCorp LP, College Station, TX, USA). For dichotomous out-
comes, the effects were expressed as the RR and 95% CI. For
continuous outcomes with different measurement scales, we
calculated the standardized mean difference (SMD) and 95% CI.11
We used Cochran’s Q test (signiﬁcance cut-off point p = 0.10) and I2
(I2 < 25%, no heterogeneity; I2 = 25–50%, moderate heterogeneity;
I2 > 50%, strong heterogeneity) to test the heterogeneity between
the studies.13,14 The pooled effects were calculated using a ﬁxed
effect model or a random effect model based on the heterogeneity
test.15,16 A Galbraith plot was used to detect the potential sources
of heterogeneity.17 A sensitivity analysis was performed by
removing one study at a time to assess the stability of the
results.18 Publication bias was assessed using a funnel plot and
Egger’s test.11
3. Results
3.1. Characteristics of studies
Figure 1 illustrates the study selection procedure. In the initial
search, 339 potentially relevant articles were identiﬁed. After
reading the titles and abstracts, we excluded 59 articles that were
duplicated publications. We next carefully read the full texts and
excluded another 268 studies, including 72 reviews, 84 uncon-
trolled trials, 22 non-relevant studies, 69 other types of studies
such as news, letters, or portraits, and 21 studies published in
languages other than English and Chinese. Finally, 12 studies were
included in this meta-analysis. The characteristics of these studies
are listed in Table 1. The sample size for each study ranged from 12
to 267, with a median sample size of 76. These studies originated
Table 1
Main characteristics of eligible studies
Author Year Country Type of wound Study design Intervention and control Age, years Number of subjects Outcomes
Markevich et al.24 2000 Israel DFU RCT MDT 53.6 (SD 15.4) 70 Healing rate
Hydrogel therapy 70
Wayman et al.22 2000 UK Venous ulcers RCT MDT 58 (range 48–72) 6 Cost of treatment
Hydrogel therapy 54 (range 40–75) 6
Sherman32 2002 USA Pressure ulcers Prospective study MDT 62 (range 26–85) 43 Healing rate
Conventional therapy 66 (range 32–91) 49
Sherman26 2003 USA DFU Retrospective study MDT 63 (range 53–74) 14 Healing rate; time to healing;
antibiotic usage
Conventional therapy 68 (range 53–82) 14
Armstrong et al.25 2005 USA DFU Retrospective study MDT 71.7 (SD 6.8) 30 Healing rate; time to healing;
incidence of infection;
amputation rate; antibiotic-free days
Standard wound care 72.7 (SD 6.8) 30
Dumville et al.3 2009 UK Venous leg ulcers RCT MDT 73.8 (SD 12.5) 180 Healing rate
Hydrogel therapy 74.3 (SD 12.8) 87
Paul et al.19 2009 Malaysia DFU Prospective study MDT with Lucilia cuprina and
subcutaneous insulin
55.3 (range 30.0–69.2) 25 Healing rate; amputation rate;
antibiotic usage
Surgical debridement and
subcutaneous insulin
55.3 (range 32.0–82.5) 29
Soares et al.23 2009 UK Venous ulcers RCT MDT 73.8 (SD 12.5) 180 Cost of treatment
Hydrogel therapy 74.3 (SD 12.8) 87
Wang et al.33 2010 China DFU/pressure ulcers Retrospective study MDT 54.1 (SD 3.7) 23 Time to healing
Conventional therapy 52.7 (SD 4.1) 20
Meng and Zhang20 2010 China Crush injury RCT MDT 46.0 (SD 6.5) 34 Time to healing
Conventional therapy 48.0 (SD 3.7) 30
Wilasrusmee et al.21 2013 Thailand DFU Retrospective study MDT 55.5 (SD 12.2) 59 Healing rate
Conventional therapy 53.4 (SD 11.4) 52
Mudge et al.,34 2014 UK Venous leg ulcers or mixed
etiology leg ulcers
RCT MDT N/A 46 Healing rate
Hydrogel therapy N/A 42
DFU, diabetic foot ulcer; RCT, randomized controlled trial; MDT, maggot debridement therapy; SD, standard deviation; N/A, not available.
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Figure 2. Comparison of the healing rates between the maggot/larval group and the control group.
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Thailand). Several studies may have included the same patients,
but they estimated different types of outcomes.3,19 There were 530
subjects who had received maggot or larval therapy and 429
subjects who had received other control therapies (e.g., hydrogel
dressing). There was no signiﬁcant difference in the age distribu-
tion between these groups (p > 0.05).
3.2. Quality assessment
Of the six RCTs, two20,21 had two types of source for high risk
bias and the other four studies3,20,22,23 had one type of source for
high risk bias. We could not assess the bias of allocation
concealment for all six studies. The authors described a random
component in the sequence generation process, such as envelope
technique22 or randomly permuted blocks.3,23 We regarded all
studies as being at a high risk of bias for blinding the participants
and caregivers because it was not feasible to continue blinding
when applying the larval therapy. Except for one study,24 all of the
RCTs described the data of missing patients. For the six non-RCTs,
the NOS score of each study ranged from seven to nine, indicating a
relatively high quality.Table 2
Evaluation of eligible studies with risk ratio or standardized mean difference
Factors No. of studies/subjects RR/SM
Healing rate
All studies 8/840 1.80 
Subgroup analysis
DFU 5/393 1.79 
Other ulcers or wounds 3/447 1.70 
Antibiotic usage 2/82 1.03 
Amputation rate 2/114 0.43 
Time to healing
All studies 4/195 0.95 
Subgroup analysis
DFU 3/113 0.79 
Other ulcers or wounds 2/82 1.16 
Cost of treatment 2/279 0.48 
DFU, diabetic foot ulcer; RR, relative risk; SMD, standardized mean difference; CI, conﬁ3.3. Pooled effect assessment
3.3.1. Healing rate
Eight studies were eligible for the meta-analysis on the healing
rate of MDT. We observed a signiﬁcant heterogeneity among these
studies (p = 0.005, I2 = 65.5%). The pooled RR of wound healing
using MDT was 1.80 (95% CI 1.24–2.60) compared with control
therapies (Figure 2). We further performed a subgroup analysis by
considering the types of wounds. The combined RRs were 1.79
(95% CI 0.95–3.38) for patients with diabetic foot ulcers (DFU) and
1.70 (95% CI 1.28–2.27) for patients with pressure or venous leg
ulcers (Table 2).
3.3.2. Infection rate, antibiotic usage, and amputation rate
Only one study25 applied the infection rate and antibiotic-free
days to compare the maggot/larval therapy with the control
therapy. In this study, the researchers observed no signiﬁcant
difference in the infection rate between the MDT (80%) and control
groups (60%) (p < 0.05), but they found a signiﬁcantly longer
antibiotic-free time period in patients receiving MDT (126.8  30.3
days) compared with control groups (81.9  42.1 days) (p < 0.001).
Two studies were eligible for the pooled estimation of antibioticD (95% CI) Heterogeneity test
Chi-square p-Value I2 (%)
(1.24–2.60) 20.27 0.005 65.5
(0.95–3.38) 16.26 0.003 75.4
(1.28–2.27) 4.01 0.135 50.1
(0.87–1.22) 0.65 0.422 0.0
(0.21–0.88) 0.55 0.460 0.0
(1.24, 0.65) 2.36 0.502 0.0
(1.18, 0.41) 0.86 0.650 0.0
(1.63, 0.69) 0.05 0.819 0.0
(1.76, 0.80) 4.12 0.043 75.7
dence interval.
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groups (27 of 39 (69.2%) in the MDT group vs. 30 of 43 (69.8%) in the
control group). The pooled RR (95% CI) was 1.03 (0.87–1.22) (Table 2).
The patients in the control group had approximately twice the risk of
undergoing amputation compared with the MDT group (RR 0.43, 95%
CI 0.21–0.88) (Table 2).
3.3.3. Time to healing
Data from four studies3,13,14,26 showed that time to healing was
signiﬁcantly shorter in the MDT group than in the control group.
The pooled SMD of time to healing was 0.95 (95% CI 1.24, 0.65,
p = 0.502) (Table 2). In addition, a subset of three studies3,14,19 (113
subjects) reported the time to healing of DFU, and two studies13,14
(82 subjects) reported the time to healing of other ulcers or
wounds. Both studies provided evidence for the role of MDT in
promoting the healing of ulcers (DFU: SMD 0.79, 95% CI 1.18,
0.41; other ulcers: SMD 1.16, 95% CI 1.63, 0.69).
3.3.4. Costs of MDT
Wayman et al.22 reported the 30-day cost for treating ulcer
patients. The costs included nursing, dressing, and larval costs.
They showed a total cost for the larva group of £491.87 (including
larva costs) compared with a cost of £1039.53 for the hydrogel
group. In another study performed by Soares et al., the cost was
£172.76 per participant per month for patients treated with MDT
compared with £164.70 for patients treated with hydrogel.23
Considering the signiﬁcant heterogeneity between these two
studies (p = 0.043, I2 = 75.7%), we used a random effect model to
estimate the combined difference in the cost (SMD 0.48, 95% CI
1.76, 0.80) (Table 2).
3.4. Sensitivity analysis and bias assessment
We used a Galbraith plot to explore the heterogeneity and to
check whether an individual study affected the results of healing
rate and time to healing of ulcers. On the Galbraith plot, all of the
studies were located within the 95% bounds (the zone of two
outer parallel lines drawn at two units over and below the
regression) from the standardized mean lnRR and SMD. We
conducted leave-one-out sensitivity analyses by removing one
study at a time to check whether the individual study inﬂuenced
the results. We found that the pooled result was not obviously
impacted by any single study. A funnel plot and Egger’s test
showed no statistical evidence of publication bias in the analysis
of either healing rate (Egger’s test: p = 0.572) or healing time
(Egger’s test: p = 0.360).
4. Discussion
Chronic wounds or ulcers are difﬁcult to treat and usually heal
slowly when conventional therapies are used. Many of these
wounds occur in patients with a poor health status, making ulcer
optimization difﬁcult to achieve. MDT, as revealed in this meta-
analysis, is more effective and efﬁcient in the debridement of
chronic ulcers compared with the conventional treatments.
The utilization of larvae for wound healing has been reported
over the last thousand years.3 A possible explanation of how
maggots combat wound infection is that the larvae can ingest
wound bacteria and kill them as they pass through their digestive
tract.27 Other mechanisms include irrigation of the wound by
increased exudate, the production stimulated by the larvae
ingesting necrotic tissues, or dilution of the wound discharge by
the maggots’ own secretions.7
Some previous clinical trials have led to the promotion of MDT
as a clinically effective treatment.28–34 ‘Effective’ in these trials was
deﬁned in various ways, including the promotion of healing, thepromotion of debridement, or a reduction in the number of
bacteria in the wound.3 The systematic review of the effects of
MDT is essential for guiding its clinical application. In this meta-
analysis, we revealed a signiﬁcant positive effect of MDT on the
healing rate of chronic wounds and a shortened time to healing in
ulcers. MDT also showed a longer antibiotic-free time period,
decreased amputation risk, and similar antibiotic usage compared
with conventional therapies. With the increased public acceptance
and medical awareness, MDT may be used more widely for
superﬁcial infections in the future. For patients with drug
resistance, chronic infections, immunosuppressive illnesses, or
diabetes, MDT may even become the ﬁrst-line treatment.
Currently, doctors usually consider MDT to be a last resort to
treat infected ulcers with peripheral vascular diseases when
conventional treatments have failed. It is recommended that early
aggressive surgical debridement with intravenous antibiotics in
combination with MDT may be more effective than these
treatments alone.3
MDT can reduce overall antibiotic use, prevent hospital
admissions, and decrease the number of outpatient visits. It is a
relatively cheap method and may save medical costs, as mentioned
above, and reduce hospital bed occupancy. In this meta-analysis,
only two articles were eligible for the cost-effective analysis. More
studies are needed to compare the cost and effectiveness of MDT
compared with traditional therapies, such as hydrogel dressing.
The complications of MDT are reported to be few and minor.1 Some
authors noted a mild febrile reaction after applying larvae to the
wound. Ethical problems, including patient recruitment and staff
acceptance, are limited. MDT is usually well tolerated by the
patient, although the escape of larvae is sometimes observed; this
can be overcome by creating appropriate dressings.1
It is important to select appropriate indexes together with
well-designed trials to judge the effectiveness of MDT. In addition
to the common outcomes mentioned above, some studies have
explored the time to debridement by MDT. For example, a study
with 105 patients found that debridement by MDT was
signiﬁcantly faster than the control therapy during the ﬁrst week
of treatment but reached the same level by day 15.31 Dumville
et al. also reported that there was no difference in the time to
debridement between the two groups, but that the rate of
debridement at any time in the MDT group was about twice that of
the hydrogel group.3 However, there are limited data for meta-
analyses. Gray performed a meta-analysis in 2008 that involved
four studies to identify the efﬁcacy of MDT for the removal of
necrotic tissue and its impact on wound healing.4 Four studies
all reported that MDT led to more rapid debridement than
conventional therapies did. However, the author stated that there
was insufﬁcient evidence to conclude that MDT is as effective as,
or more effective than, other debridement methods, due to the
methodological limitations of these studies.4 For example, there
was only one prospective randomized clinical trial, but it used
cost outcomes rather than efﬁcacy as its main outcome measure.
Since then, several new studies on the effects of MDT on chronic
wounds or ulcers have been reported, making MDT eligible for
an updated meta-analysis. By searching relevant databases,
we included 12 studies for this systematic review, including
530 subjects who had received maggot or larval therapy and
429 subjects who had received control therapies. By using
multiple outcome measures, we found that the healing rate
was signiﬁcantly higher and the time to healing was shorter in the
MDT groups compared to control groups.
Although we identiﬁed positive effects of MDT on treating
wounds or ulcers in our current updated meta-analysis, several
limitations in this study should be noted. First, the number of
relevant studies eligible for the meta-analysis was relatively small,
resulting in lower statistical power. Second, the therapies used in
X. Sun et al. / International Journal of Infectious Diseases 25 (2014) 32–37 37the control groups varied in different studies, which may have
inﬂuenced the effect estimation of MDT. Third, in some non-RCTs,
MDT might have been used primarily as a salvage tool when almost
all else had failed, which would lead to biased healing outcomes.
Finally, most of the studies were carried out in Asian populations,
thus limiting the generalization of the ﬁndings. Moreover, the
different patient selection criteria, chemotherapeutic protocols,
and follow-up periods were also possible explanations for the
heterogeneity in the studies.
In conclusion, MDT not only shortened the healing time but also
improved the healing rate of chronic ulcers; therefore, it may be a
feasible alternative in the treatment of chronic ulcers.
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